Displaying drugs 11376 - 11400 of 11761 in total
Paltusotine
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety …
Oxelumab
Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Investigational
Matched Description: … Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention …
SLV319
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
NXN-188
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase …
Octopamine
Octopamine is structurally similar to norepinephrine. It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.
Experimental
Matched Description: … It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World …
Clinafloxacin
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … Clinafloxacin is a fluoroquinolone antibacterial currently under research. …
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of …
Modimelanotide
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
Rocapuldencel-T
Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).
Investigational
Matched Description: … Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A …
TAK-754
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
Matched Description: … Developed by Takeda, it is being investigated for the treatment of hemophilia A.[A259831] …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic …
Fiboflapon
Investigational
Vasomera
Investigational
Centanafadine
Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).
Investigational
Matched Description: … Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the …
Egaptivon pegol
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding …
PH-284
PH-284 belongs to a new family of new chemical entities called vomeropherins. Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. This binding produces neural impulses that are transmitted by specific...
Investigational
Matched Description: … PH-284 belongs to a new family of new chemical entities called vomeropherins. ... Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device …
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
Synephrine
Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid. It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine.
The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source...
Experimental
Matched Description: … The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source of ... some confusion however m-synephrine refers to a related drug more commonly known as phenylephrine. …
Verubecestat
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.
Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
Matched Description: … In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent ... and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of …
Virus Specific T-Cell
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and...
Investigational
Matched Description: … Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. ... These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. …
Methapyrilene
Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Withdrawn
Matched Description: … Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. …
SB-249553
SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Investigational
Matched Description: … SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. …
Telisotuzumab vedotin
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Investigational
Matched Description: … Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety …
ONO-8539
ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).
Investigational
Matched Description: … ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal …
Reloxaliase
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
Matched Description: … Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. …
Displaying drugs 11376 - 11400 of 11761 in total